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Abstract 
Objective: This review aims to provide an overview of the current knowledge available on 
the nature and extent of the relationship between external-beam radiotherapy (RT) and fear of 
cancer recurrence (FoR).  
Methods: PubMED, Medline and Embase databases were searched to identify relevant 
studies. Systematic review procedures were followed including a quality assessment. Meta-
analysis of suitable studies was conducted. 
Results: Twenty-five eligible studies were included in the systematic review and fifteen of 
them were included in further meta-analysis. Meta-analysis of the available data confirmed a 
weak relationship between RT and FoR (15 studies, 9567 patients, overall r = 0.053, 95%, CI: 
0.021-0.085, P=0.001). Subgroup analysis based on cancer site (breast cancer versus other 
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types of cancer) revealed that the correlation between RT and FoR was statistically 
significant in ‘other cancer’ group (P˂0.001) but was nonsignificant in ‘breast cancer’ group 
(P=0.538). 
Conclusions: While meta-analysis reports a statistically significant association between 
cancer patient's FoR and the receipt of RT, these results should be interpreted with caution 
due to significant variability between studies. Further longitudinal studies should be 
conducted to address the trajectory of FoR over RT in greater detail. Standardized validated 
FoR measurement would assist this investigation. 
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Background 
Radiotherapy is a treatment frequently used for cancer patients involving the use of high-
energy radiation [1]. Almost a half to two-thirds of cancer patients will have radiotherapy as 
part of their treatment plan (adjuvant treatment), and almost 75% of patients who received 
radiotherapy are treated to cure the cancer, rather than to relieve symptoms such as pain [2]. 
Radiotherapy is delivered in two ways – external to the body by a machine (external-beam 
radiation treatment, RT) or within the body by judicious siting of radioactive material 
(brachytherapy, BT). According to the latest data, about 88 percent of patients received RT  
while the remaining 12 percent of patients received BT [1, 2].  
 
The fear of recurrence (FoR) is common among cancer patients and survivors [3]. FoR is 
considered to persist long after the termination of treatment and into the chronic stage of 
survivorship [3]. FoR is reported by 33% to 96% of cancer patients [4-7] and may predict 
poorer quality of life outcomes up to six years after diagnosis [8]. Cancer patients who suffer 
from high FoR report negative behaviour change (e.g. avoidance behaviour and excessive 
personal checking behaviours) [9], increased health service use [10], inability to plan for the 
future [11] and significant psychological distress, such as depression, anxiety and post-
traumatic stress symptoms [4, 12-14].  
 
In recently published studies, a variety of factors were found to be associated with patients’ 
FoR level [3]. Demographic characteristics such as, female gender, young age, and a higher 
level of education have been reported to be related with higher FoR. In addition, studies have 
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shown that white women are more likely to have higher worry levels than African Americans 
[15-21]. Various treatment characteristics, such as having received a mastectomy or 
chemotherapy, and having more physical symptoms have been identified as strong predictors 
of FoR.  However, these findings are not always consistent [16, 17, 21-23]. For example, 
Mellen et al. [24] and Leake et al. [22] reported that treatment type (chemotherapy, surgery 
or radiotherapy) was not related to patient’s FoR. Llewellyn et al. [8] reported that FoR had 
no association with any socio-demographic or treatment factors. 
 
To date, although studies have reported that cancer patients may suffer from different 
psychological problems such as anxiety, depression as well as psychological distress, in the 
course of RT [25, 26], there have been few studies investigating, specifically, the relationship 
between patient’s FoR and RT. A previous systematic review by Simard et al. [3] reported a 
weak to moderate association between treatment type (surgery/chemotherapy/radiotherapy) 
and FoR. However, the result is not entirely convincing as it combines RT and BT. They are 
different treatment applications, as previously highlighted, and are likely to be perceived by 
patients with a variety of psychological representations. Therefore, our research team decided 
to focus deliberately on a specific study of RT and its possible association with FoR and 
exclude BT. The reasons to focus, solely on RT, as opposed to, or in combination with BT, is 
that RT is the most frequent medium of treatment using ionizing radiation which involves 
specific units including resource intensive physical and capital environments in the design of 
clinics and specialist units, while BT is more novel, delivered on a smaller scale and with less 
public awareness of the procedure. There may be value to the health provider team to learn of 
patient reaction to their treatment and enable additional avenues of intervention to assist 
patients through the experience of a common treatment delivery in cancer care.  
 
The aim of this study is to conduct a systematic overview and meta-analysis of FoR-RT-
related quantitative studies to test the association between cancer patient’s FoR and the 
receipt of RT. By systematically summarising current knowledge, an indication of the 
influence of RT on FoR may be provided. 
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Method  
Literature search 
The study was conducted in accordance with the PRISMA guidelines for a systematic review 
and meta-analysis [27]. The Ovid MEDLINE, PubMed and Ovid EMBASE (1974 to May, 
2016) databases were utilised. The key search terms were: cancer/carcinoma/neoplasm, 
fear/worry/concern, recurrence/progression/return, and radiation/radiotherapy/radiation 
therapy. Searching was performed using the OR and AND functions. The detailed search 
strategy is outlined in Supplementary Table 1. The reference lists of identified review articles 
as well as all included studies were also screened manually for any additional relevant studies. 
No restrictions were placed on publication date.  
 
Inclusion and exclusion criteria 
To be included in the review, references had to (a) be published in a peer-reviewed journal; 
(b) be written in English; (c) include adult patients; (d) include patients who had been treated 
with RT (with/without other treatment type) (e) be quantitative studies and report FoR results. 
Studies using similar, but not accurate key words, such as ‘fear of dying’, ‘fear of the worst 
happening’ or ‘chemoradiotherapy’ were excluded. Additionally, studies were excluded if 
they were case studies, commentaries, reviews, conference abstracts, dissertations, as well as 
qualitative studies. Studies were screened for eligibility and codetermined by two reviewers 
(YY and GH). 
 
Data extraction and quality assessment 
The search identified potential eligible records. After removing duplicate studies, titles and 
abstracts of search results were reviewed and unsuitable studies were excluded. Then full 
papers were obtained and examined, and articles that fulfilled the inclusion criteria for the 
review were included. For each study, the following information was gathered: first author’s 
name, year of publication, study design and basic demographic information, such as country 
where the study was conducted, age, and sample size. In addition, cancer type, measure of 
FoR and main findings were noted. 
 
The quality of each included study was assessed using QualSyst criteria (Standard Quality 
Assessment Criteria for quantitative studies [28], see Supplementary Table 2). Items were 
scored on the specific criteria (Yes=2, Partial=1, No=0). A summary score was calculated for 
each paper and defined as strong (score of ˃0.80), good (0.70-0.80), adequate (0.50-0.70), or 
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limited (˂0.50). Any paper of limited quality was excluded. In case of disagreement about a 
paper, reviewers (YY and GH) repeated their assessment of the study and in discussion 
reached consensus. 
Statistical Analysis 
On completion of the systematic review, a quantitative meta-analytic approach was applied. 
The programme Comprehensive Meta-analysis was employed [29]. The effect size was 
calculated by applying routines to derive a correlation (r) with accompanying 95% 
confidence intervals (CI). The effect size was calculated by r but not Hedges’ g because 
several of the included articles [20, 30, 31] had very large sample sizes. The corresponding 
authors of articles with incomplete data were contacted by email to obtain the required data 
unavailable in the published article. Studies for which the corresponding authors could not be 
reached were subsequently excluded from the meta-analysis.  
 
Statistical heterogeneity among the articles was reported by the Q statistic, a P-value less than 
0.10 or an I-squared value greater than 50% was considered as substantial heterogeneity [29]. 
If substantial heterogeneity was observed, the correlation will be calculated according to the 
random-effects model, otherwise, the results would be calculated based on the fixed-effects 
model. The selection of the computational model was based on the understanding of the 
underlying distribution. Under the fixed-effect model we assumed that the true effect size was 
the same in all studies, while in the random-effect meta-analysis, we expected the effect size 
to be similar but not identical across studies. True effect sizes were assumed to be normally 
distributed under this model [29]. 
 
A subgroup analysis based on the cancer site was performed (breast cancer versus other types 
of cancer). The percentage of breast cancer patients treated with RT has increased 
substantially during the past two decades [32]. According to the best available evidence, RT 
would be recommended in 83% (95% confidence interval, 82-85%) of patients with breast 
cancer [33]. In the articles included in the meta-analysis, over half of the patients were 
diagnosed as having breast cancer (5680 out of 9567 patients, 59%). Therefore, the subgroups 
breast vs. other cancers were chosen pragmatically, to investigate the potential value of 
cancer type on the relationship between RT and FoR. In addition, Rosenthal’s ‘fail safe N’ 
procedure was adopted to estimate the number of negative studies that would be required to 
overturn the total aggregated result. Funnel plot and Egger’s regression intercept test were 
also performed in this review in order to assess publication bias. 
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Results 
Characteristics of included studies 
The search process is shown in Supplementary Figure 1. The literature search of three 
databases identified 751 references. Duplicates were excluded revealing 356 titles. 
Examination of abstracts for appropriateness left 55 articles. After retrieving full texts and 
further assessment, 25 studies were included in the systematic review. All of them were 
evaluated using the QualSyst criteria, and none of them had the score of limited quality (see 
Table 1). However, 10 studies were excluded from further meta-analysis (one prevalence rate 
study [34], two longitudinal studies [35, 36], one strong outlier in funnel plot [37], and six did 
not report specific statistic values [16, 22, 24, 38-40]). Therefore, 15 articles were finally 
included in the meta-analysis.  
 
The publication dates of the studies included ranged from 1981 to 2016. One article was 
published in the 1980s, eleven in the 2000s, and the remaining studies were published since 
2010. Thirteen studies were conducted in North America, nine in Europe, and one each in 
Australia, Korea and China. The cumulative sample size including all studies was 11,129 
(ranged from 30 to 2671), and the mean age of cancer patients participating in all studies 
ranged from 44 to 72 years, with 6 studies not reporting a median or mean age. Regarding the 
FoR instruments, standardized assessment measures were lacking and self-reported 
questionnaires were frequently used (as opposed to standardised interview). The number of 
scale items ranged from 1 to 42 and only ten studies reported the validity/reliability of the 
measurement. Main characteristics and findings of the included publications are presented in 
Table 2. 
 
Systematic review 
Twenty-five studies were included in the systematic review, one article [34] studied the 
prevalence rate of FoR after RT in mainland China, two longitudinal studies [35, 36] 
measured patient’s FoR level over/after RT, and the remaining twenty two studies [11, 16, 19, 
20, 22, 24, 30, 31, 37-50] evaluated the impact of RT on patient’s FoR. Conflicting evidence 
was found among these 22 studies. Seven articles [19, 20, 40, 44, 46, 49, 50] suggested that 
RT was associated with higher FoR. One [30] suggested that patients who had received RT 
were less likely to experience moderate/high FoR (OR 0.72, CI 0.55-0.94), while the 
remaining fourteen studies reported that RT and FoR were not systematically associated [16, 
22, 24, 31, 37-39, 41-43, 45, 47, 48, 51]. 
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Meta-analysis 
The meta-analysis statistics derived from the 15 articles consisted of the following: P-value 
(nine articles [11, 20, 42, 43, 45-47, 49, 50]), correlation coefficients (three articles [19, 41, 
44]), odds ratios (two article [30, 31]) as well as means and SDs (one article, [48]). 
Heterogeneity test showed that the Q-value of this review was 29.46, the P-value was less 
than 0.1, and the I-squared value was greater than 50% (P-value=0.009; I-squared=52.482 ), 
therefore, a random-effect model was used. By using random-effect weights, the summary 
estimate of the correlation was 0.053 with a 95% confidence interval (CI) of 0.021 to 0.085. 
The Z-value was 3.275, and the P-value was 0.001 (two tailed).  
 
Subgroup analysis showed that cancer type was linked to the degree of association, namely, 
the ‘other cancer’ group showed a statistically significant correlation between RT and FoR 
(P˂0.001) while the ‘breast cancer’ group showed a nonsignificant result (P=0.538, see 
Figure.1). The correlation value of ‘other cancer group’ (r=0.089) is significantly higher than 
‘breast cancer group’ (r=0.014, P=0.001). Additionally, the fail-safe-N-value, which 
calculates the number of missing studies that would bring the P-value to less than the alpha of 
1.96 was found to equal 64. In the examination of the funnel plot, 15 studies were noticeably 
distributed symmetrically about the mean effect size (see Supplementary Figure 2). Egger’s 
regression intercept test showed no statistically significant P-value (intercept=0.448, SE=0.61, 
T=0.74, and P=0.48), therefore, we assume that no apparent publication bias was found in 
this review. 
 
Discussion 
This is the first systematic review and meta-analysis that explores the association between RT 
and FoR. Overall meta-analysis indicated that patient’s FoR level was statistically 
significantly associated with the receipt of RT, though the correlation is weak. This result 
should be interpreted with great caution because even though a positive association is shown, 
it is questionable if this relationship is clinically significant. A careful inspection of the 
various studies within this review may signal an understanding of why this relationship, 
although positive, is not strong.  
 
The collective of breast cancer studies showed a nonsignificant relationship between RT and 
FoR. One possible reason for this is that Koch’s study reported 2671 patients with a negative 
correlation between RT and FoR. This large-sample study dominated the overall breast 
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cancer group sample size and had therefore a strong influence on the overall subgroup result. 
In addition, among all the articles, this was the only study that reported RT as a protective 
factor for cancer patients. Removal of this study resulted in a significant positive association 
consistent with subgroup result for the other cancer sites.  
 
According to the systematic review, seven studies demonstrated the positive association of 
RT receipt with greater FoR. The side effects and symptom burden caused by RT may 
contribute to this result. Significant side effects are common with RT and contribute to the 
symptom burden. Previous research revealed that RT-induced side effects are usually chronic, 
progressive, and can be sustained for many years after the end of treatment [52]. Strong 
evidence was found for an association between residual physical symptoms and elevated FoR 
[24]. Therefore, it is reasonable to conceive that RT-related symptoms, such as tiredness and 
skin reaction, might be viewed by patients as a constant reminder of their cancer or be 
misinterpreted as an indicator of cancer recurrence, which leads to higher FoR score. Also, 
some patients may believe that the effect of RT may be a risk factor for new malignancies. 
The results point to the need for patient education about common RT side effects, both before 
and after RT, to provide patients with sufficient knowledge that they wish to receive. The aim 
of this additional attention to patient RT health literacy is to diminish FoR development.  
 
Another reason may be patients’ doubts about the efficacy of RT. Due to the more 
conservative nature of RT, patients may feel less confident and hold concern that the 
tumour/cancer still exists inside their body, thus, patients are more likely to report higher FoR. 
One study [53] has found out that conservative treatment such as endoscopic therapy for 
oesophageal cancer was associated with higher FoR, which may relate to patients’ doubts 
about whether the cancer has been fully removed. A further reason for radiotherapy being 
interpreted by the patient as linked to FoR may be that they believe they have a more serious 
form of cancer which requires more intensive treatment. Some patients may regard the extra 
treatment as a useful and important protection against further disease. However a proportion 
may well regard the additional mode of treatment with a sinister interpretation such as the 
disease is difficult to treat and is persistent, even in small traces. 
 
There are, inevitably, limitations in this review that require consideration. These include the 
overall study sample’s homogeneity (mostly white, old cancer patients), which precludes 
generalizations to more diverse populations or younger people with cancer, especially Asian. 
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A lack of longitudinal studies over the course of RT is another limitation of this review. 
Many studies are cross-sectional with follow-up assessment. Further studies should focus 
attention on the development of FoR and how RT makes an influence on it. Moreover, the 
lack of standardized validated questionnaires is also an important fact which cannot be 
ignored. FoR was measured using a range of scales among the included articles, and the 
number of items varied widely. The publication dates of the studies included also varied 
significantly (ranged from 1981 to 2016). RT techniques have improved considerately in the 
past 15 years, therefore, patients may report different experience/side effects to RT. Last but 
not least, this review only involved a small number of studies, only 15 articles were included 
in meta-analysis. No attempt was made to search for non-English publications or unpublished 
articles. Hence, we suggest that our research findings must be interpreted with caution. 
 
Interventions in cancer patients may be warranted to alleviate their FoR and other 
psychological distress during RT. Such interventions could include the offer of counselling 
and psychotherapy providing adequate treatment-relevant information, and facilitating the 
support network from both health professionals and families. Cancer survivors who have high 
levels of FoR should be carefully identified and invited into appropriate psychological 
programs to assist them and help address overall negative effects on health-related quality of 
life. 
 
Conclusions  
Though meta-analysis showed a statistically significant association between cancer patient’s 
fear of recurrence and the receipt of external-beam radiation treatment, the relationship might 
not be clinically significant. Further longitudinal studies should be conducted to address the 
trajectory of FoR over RT in a more detailed way, and standardized validated FoR 
measurement should be developed and used. 
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Table 1. Quality assessment of included studies 
Study Item 1 Item 2 Item 3 Item 4 Item 5-7 Item 8 Item 9 Item 10 Item 11 Item 12 Item 13 Item 14 Quality 
 Question 
Describe 
Study 
Design 
Method 
of 
subject 
Subject 
characteristics 
Intervention 
/blinding 
Outcome 
/measure 
Sample 
size 
Analytic 
methods 
Estimate 
of 
variance 
Confounding 
control 
Result 
Report 
Conclusion  
Simard 2 2 2 2 N/A 2 2 2 2 1 2 2 Strong 
Janz 2 2 2 2 N/A 2 2 2 1 1 2 2 Strong 
Hong 2 2 2 1 N/A 2 2 2 2 2 1 2 Strong 
Tewari 2 2 2 1 N/A 1 2 2 1 2 2 2 Strong 
Van de Wal 2 2 2 2 N/A 2 2 2 1 1 2 2 Strong 
Deimling 2 2 2 2 N/A 2 2 2 1 2 2 2 Strong 
Liu 2 2 2 2 N/A 2 2 2 1 0 2 2 Strong 
Mellon 2 2 2 2 N/A 2 2 2 2 2 1 2 Strong 
Sung 2 2 2 2 N/A 2 2 2 2 0 2 2 Strong 
Stanton 2 2 2 1 N/A 2 1 2 1 2 1 2 Strong 
Hong 2 2 2 1 N/A 2 2 1 2 0 2 2 Strong 
Skaali 2 2 2 2 N/A 1 2 2 2 0 2 2 Strong 
Bergman 2 2 2 2 N/A 2 2 2 2 2 2 2 Strong 
Rogers2 2 2 2 2 N/A 2 2 2 1 0 2 2 Strong 
Koch 2 2 2 2 N/A 2 2 2 2 0 2 2 Strong 
Rogers1 2 2 2 2 N/A 2 2 1 0 0 2 2 Good 
Perrucci 2 2 2 1 N/A 2 2 2 0 0 2 2 Good 
Wiley 2 2 2 2 N/A 2 1 2 1 0 1 2 Good 
Ghazali 2 2 2 1 N/A 2 2 2 1 0 1 2 Good 
Rabin 2 2 1 1 N/A 2 1 2 2 1 1 2 Good 
Mehta 2 2 2 2 N/A 2 2 1 1 0 1 2 Good  
Hartl 2 2 2 1 N/A 2 2 2 0 0 2 2 Good  
Humphris 2 2 2 1 N/A 1 1 2 1 1 1 2 Good 
Leake 2 2 2 2 N/A 1 2 1 0 0 1 2 Adequate 
Northouse 2 2 1 2 N/A 2 0 1 0 0 1 2 Adequate 
Quality assessment of included studies. 
1
: Rogers (2010); 
2
: Rogers (2015). 
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Table 2. Characteristics of the 25 included studies.  
First Author 
Year, Country 
Study Design Cancer Type Sample size 
analysed 
Age at survey 
Mean (SD) 
FoR instruments Reliability Main findings 
Simard,  
2009, Canada 
Cross-
sectional 
Breast 
prostate 
 lung  
colorectal 
N=600 Breast 59.0 (0.6) 
Prostate 69.1 (0.5) 
lung 62.0 (1.5) 
 colorectal 61.6 (1.3) 
Fear of Cancer 
Recurrence Inventory 
(FCRI) 42-item 
Cronbach’s 
alpha=0.95, test-
retest r=0.89 
A significantly higher FCR was found in 
cancer patients who had RT 
(P=0.005) 
Janz,  
2011, USA 
Cross-
sectional 
Breast N=1837 56.8 (11.4) Worry about recurrence 
scale (3-item, rage 1-5) 
Cronbach’s 
alpha=0.88 
RT was associated with higher FoR 
(P<0.001) 
Hong,  
2010, USA 
Longitudinal+
% 
Prostate N=584 unknown Kornblith Scale 
(CaPSURE 
Questionnaire) 
unknown Patients who received radiation and/or 
hormonal therapy experienced greater 
FoR (OR 2.78, 95%, CI 1.21-6.39) 
Rabin,  
2004, USA 
Longitudinal+
% 
Breast  N=69 48.4 (9.3) 
Range: 30-73 
Study-designed FOR 
Scale 
Cronbach’s 
alpha=0.84, test-
retest r=0.50 
RT (received vs. did not receive) was 
unrelated with FoR  
Tewari,  
2014, USA 
Cross-
sectional 
Breast  N=392 unknown face-to-face  
interview (single 
question) 
unknown Having had RT was correlated with 
increased worry about recurrence 
(P=0.04) 
Deimling,  
2006, USA 
Cross-
sectional 
Breast 
Colorectal 
Prostate 
N=321 72.3 (7.5) Cancer-related heath 
worries scale (4-item) 
Cronbach’s 
alpha=0.84 
Having had RT was significantly related 
to worry of recurrence but was not a 
significant predictor (r=0.13, P˂0.05) 
Mehta,  
2003, USA 
Longitudinal* Prostate  N=53 71.6 Fear of Recurrence Scale 
(5-item) 
unknown FoR was more severe before RT, 
improved after RT but didn’t change 
substantially in the 2 years thereafter 
Hartl,  
2003, Germany 
Cross-
sectional 
Breast  N=274 60.0 (11.6) QLQ-C30-V2.0 
questionnaire 
unknown RT had no significant impact on patient’s 
FoR (P=0.75) 
Liu,  Longitudinal+ Breast N=506 58 (10) First four items from the Cronbach’s RT was unrelated to cancer patient’s FoR 
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2011, USA Concern About 
Recurrence Scale 
(CARS)  
alpha=0.87 (P=0.87) 
Humphris,  
2003, UK 
Cross-
sectional 
Orofacial  N=87 58.3 (11.3) Single item from the 
Worry of Cancer Scale 
unknown RT was unrelated to cancer patient’s FoR 
(r=-0.08) 
Northouse,  
1981, USA 
Cross-
sectional% 
Breast  N=30 Range: 34-74  Fear of Recurrence 
Questionnaire (22-item) 
72% of the items 
having correlations 
above 0.6 
RT was not significantly related to 
cancer patient’s FoR 
Mellon, 
2007, USA 
Cross-
sectional% 
Breast 
Colon 
Uterine 
Prostate 
N=123 65 (6.2) 
Range: 52-75 
Fear of Recurrence 
Questionnaire (22-item) 
Reliability 
coefficients=0.92 
RT was not related to cancer survivors or 
family caregivers’ FoR 
Leake,  
2001, Australia 
Cross-
sectional% 
Gynaecological 
malignancies 
N=202 unknown A single FoR question unknown RT was not related to cancer patient’s 
FoR 
Rogers, 
2010, UK 
Cross-
sectional 
Head and Neck N=123 unknown 7-item Fear of 
Recurrence questionnaire 
unknown There was no relationship between RT 
and cancer patient’s FoR (P=0.86) 
Sung,  
2011, Korea 
Cross-
sectional 
Thyroid N=357 43.9 (11.3) Fear of Progression 
questionnaire (FoP-Q) 
unknown Use of postoperative radiation treatment 
had no significant effect on cancer 
patient’s FoP (P=0.414) 
Stanton, 
2002, USA 
Longitudinal+
% 
Breast  N=70 52.63 (11.94) 
Range: 30-80 
6-item from 22-item fear 
of recurrence 
Questionnaire 
unknown RT was not significantly related to 
cancer patient’s FoR 
Hong,  
2015, China 
Cross-
sectional 
Nasopharynx N=216 47.81 (10.75) QLQ-C30-V3.0 
questionnaire 
unknown FoR was a frequent RT-induced 
psychological distress in China 
(Prevalence rate: 18.52%) 
Perrucci, 
2015, Italy 
Longitudinal* Breast  N=117 unknown 3-item FoR Scale unknown FoR was unchanged at a median of 20 
and 80 months after partial (P=0.483) or 
whole breast irradiation (P=0.417) 
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Skaali,  
2009, Norway 
Cross-
sectional 
Testicular N=1336 44.8 (10.1) Single question of FoR unknown RT was not associated with cancer 
patient’s FoR (P=0.85) 
Wiley,  
2013, USA 
Cross-
sectional^ 
Choroidal 
melanoma 
N=98 63.71 (range-24-88) The concern of 
recurrence scale 
Cronbach’s 
alpha=0.68 
No difference in concern of recurrence 
between RT/BT group and enucleation 
group (Fisher’s Z=1.280) 
Bergman,  
2009, USA 
Longitudinal+ Prostate N=78 63 (8) The memorial anxiety 
scale (5-item) 
unknown RT was not associated with FoR 
(P=0.97) and it did not predict change in 
FoR from baseline to 12 months (P=0.24) 
Rogers,  
2015, UK 
Cross-
sectional 
Head and Neck N=513 65 (range 58-72) Single Item FoR unknown There was significant association 
between having had RT with higher FoR 
(P=0.001) 
Koch,  
2013, Germany 
Cross-
sectional 
Breast N=2671 65 FoP-Q-SF Cronbach’s 
alpha=0.89 
Patient having undergone RT was less 
likely to experience moderate/high FoR 
(OR=0.72 (0.55-0.94)) 
Ghazali, 
2013, UK 
Longitudinal+ Head and Neck N=189 62 (12) 
Range 24-87 
7-item FoR 
Questionnaire 
unknown RT (received vs. did not receive) was not 
associated with FoR level 
(M(SD):19.20±9.40 vs. 17.2 ±8.10) 
Van de Wal , 
2016, 
Netherlands 
Cross-
sectional 
Prostate N=283 70 (range 54-89) Cancer Worry Scale Cronbach’s 
alpha=0.88 
 RT is associated with higher FCR (t=-
2.033; P=0.043) 
Abbreviations: RT: extern-beam radiation treatment; FoR/FCR: Fear of cancer recurrence. FoP: fear or cancer progression; Tx: treatment; 
+ Longitudinal design but not over the radiation treatment phase 
* Longitudinal design over/after the radiation treatment phase 
% Articles excluded from the meta-analysis - no specific statistical value 
^ Article excluded from the meta-analysis - Strong outlier in funnel plot 
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